Abbott Laboratories (ABT) News Today

Abbott Laboratories (NYSE:ABT) is seeing mixed analyst actions and investor reactions following its Q2 earnings beat, updated guidance and multiple price-target changes.

• Positive Sentiment: Jefferies upgraded ABT from “hold” to “buy” and raised its price target to $145, reflecting growing confidence in the company’s prospects. Abbott Laboratories (NYSE:ABT) Upgraded at Jefferies Financial Group
• Positive Sentiment: Bank of America Securities reiterated a buy rating on ABT, citing its attractive valuation amid robust growth prospects and market overreaction. Buy Rating on Abbott Laboratories: Attractive Valuation Amid Growth Prospects and Market Overreaction
• Positive Sentiment: MarketBeat’s Q2 2025 “Buy: Growth & Yield” report highlights ABT’s safe dividend, share-repurchase program and strong pipeline as long-term drivers. Why Abbott Laboratories Is a Q2 2025 Buy: Growth & Yield
• Positive Sentiment: Zacks notes ABT shares are technically oversold and could be poised for a rebound as analysts lift their earnings forecasts. Down 9.0% in 4 Weeks, Here's Why Abbott (ABT) Looks Ripe for a Turnaround
• Neutral Sentiment: ABT is featured in MarketBeat’s list of “Best Pharmaceutical Stocks to Follow Now,” underscoring its prominence in the sector. Best Pharmaceutical Stocks To Follow Now - July 17th
• Neutral Sentiment: CEO Robert Ford described the post-earnings selloff as “a little bit of an overreaction,” emphasizing confidence in Abbott’s long-term fundamentals. Abbott Laboratories CEO calls post-earnings stock decline 'a little bit of an overreaction'
• Negative Sentiment: Wells Fargo cut its ABT price target to $142 from $147, despite keeping an overweight rating, weighing on the stock. Wells Fargo & Company Lowers Abbott Laboratories (NYSE:ABT) Price Target to $142.00
• Negative Sentiment: Raymond James trimmed its target to $141 (outperform), suggesting more modest upside. Raymond James Financial Has Lowered Expectations for Abbott Laboratories (NYSE:ABT) Stock Price
• Negative Sentiment: BTIG reduced its ABT price target to $145 while maintaining a buy rating, reflecting lowered visibility. BTIG Research Cuts Abbott Laboratories (NYSE:ABT) Price Target to $145.00
• Negative Sentiment: Shares gapped down after Abbott narrowed its full-year EPS guidance, triggering time-to-sell calls. Abbott Laboratories (NYSE:ABT) Shares Gap Down - Time to Sell?
• Negative Sentiment: InsiderMonkey reports ABT shares fell over 8% on the back of lower full-year guidance, reflecting investor disappointment. Abbott Laboratories (ABT) Drops on Lower Full-Year Guidance